NCCN Guidelines for HR+ HER2 Metastatic Breast Cancer
1 Views
administrator
07/03/23
Debu Tripathy, MD, and Hatem Soliman, MD, reflect on the NCCN guideline criteria and patient factors that play into decision making for frontline therapy in hormone receptor–positive metastatic breast cancer.
-
Category
Show more
Facebook Comments
No comments found